The peptide market is largely unregulated. There is no FDA oversight of research peptide vendors, no mandatory testing standard, and no enforcement mechanism that prevents a vendor from shipping you underdosed, contaminated, or completely mislabeled product and calling it "99% pure."
The only protection you have is the Certificate of Analysis — and only if you know how to read one. A COA that simply says "purity: 99%" with no supporting data is worth nothing. A proper COA is a structured analytical document that lets you independently verify what is in your vial before you open it.
This guide walks through every component of a legitimate COA, explains what each test actually measures, and gives you a practical checklist to apply before placing any order.
What a COA actually is
A Certificate of Analysis is an analytical document issued by a laboratory that has tested a specific batch of a compound. It reports the results of that testing — what the compound is, how pure it is, and whether it meets specified quality standards.
For research peptides, a complete COA should contain all of the following:
- Laboratory name and accreditation — the testing facility must be independently verifiable
- Batch or lot number — must match the number on your vial
- Date of analysis — indicates how recent the testing is
- Compound identity — confirmed via mass spectrometry
- Purity percentage — measured by HPLC with supporting chromatogram
- Method used — HPLC, LC-MS, or both
Premium vendors additionally include endotoxin (LPS) testing, residual solvent analysis, and in some cases moisture content. These are not universal requirements but are meaningful differentiators.
Here is what a well-structured COA looks like at a glance:
HPLC — how purity is measured
High-Performance Liquid Chromatography (HPLC) is the standard method for measuring peptide purity. It works by pushing the sample through a column under high pressure, separating the target compound from impurities based on how they interact with the column material. The result is a chromatogram — a graph showing peaks for each component detected.
What the chromatogram tells you
The area under each peak corresponds to the quantity of that component in the sample. A peptide at 99% purity should produce a chromatogram with one dominant peak — the target compound — and minimal smaller peaks representing trace impurities.
The purity percentage is calculated as: (area of target peak ÷ total area of all peaks) × 100.
Purity standards
| Purity level | Assessment | Suitable for |
|---|---|---|
| ≥99% | Excellent | All research applications. Top-tier vendors consistently achieve this. |
| 98–98.9% | Acceptable | Most research protocols. Still legitimate if documentation is otherwise strong. |
| 95–97.9% | Marginal | Acceptable only for non-critical applications. Ask for explanation of impurities. |
| Below 95% | Inadequate | Not considered research-grade. Should not be used in any serious protocol. |
Mass spectrometry — confirming identity
HPLC tells you how pure the sample is. Mass spectrometry (MS) tells you what it actually is. These are two completely different questions, and both matter.
Mass spectrometry measures the molecular weight of the compound by ionizing it and measuring how the ions move in a magnetic or electric field. The result is a mass spectrum showing the observed molecular weight of the compound in the sample.
Why you need both HPLC and MS
A sample can be 99% pure and still be the wrong compound. If a vendor accidentally swaps vials, mislabels a batch, or uses a lower-cost peptide analogue in place of the target compound, HPLC will show high purity — because whatever is in the vial is consistently present. Only mass spectrometry can confirm that the compound's molecular weight matches the target.
For each peptide, there is a known theoretical molecular weight. The mass spec result should match this within a small tolerance. Some reference molecular weights:
| Compound | Expected MW | What a mismatch means |
|---|---|---|
| BPC-157 | 1419.54 Da | Wrong compound or synthesis error |
| GHK-Cu | 401.91 Da | Possible missing copper complexation |
| Retatrutide | ~4683 Da | Wrong sequence — critical to verify |
| Ipamorelin | 711.87 Da | Possible substitution with cheaper GHRP |
| CJC-1295 (DAC) | ~3647 Da | May be no-DAC version mislabeled as DAC |
Endotoxin testing — the overlooked test
Endotoxins (also called lipopolysaccharides or LPS) are fragments of bacterial cell walls that can contaminate peptide products during synthesis or lyophilization. They are invisible, odorless, and undetectable without specific testing. Even trace amounts can cause significant inflammatory responses.
The Limulus Amebocyte Lysate (LAL) assay is the standard test for endotoxin detection. It uses a clotting enzyme from horseshoe crab blood that reacts in the presence of bacterial endotoxins.
Why most vendors skip it
Endotoxin testing adds cost and complexity to quality control. As a result, the majority of research peptide vendors do not run it. Vendors who do include LAL results in their COAs — like Ascension Peptides and some batches from Paramount Peptides — are operating at a meaningfully higher quality standard.
For any peptide that will be used in injectable-format research protocols, endotoxin-free documentation should be considered a requirement, not a bonus.
Lot number traceability — the chain of custody
Every legitimate COA is batch-specific. The lot or batch number printed on the COA must match the lot number on your physical vial. This creates a traceable chain of custody: you can verify that the specific vial in your hand was tested and that the document you're reading applies to that exact batch.
What lot number problems look like
- No lot number on the vial — cannot link the vial to any COA document
- Undated COA — cannot verify testing was performed on the current batch
- Generic COA with no lot number — one document reused across multiple batches, meaning the testing is not batch-specific
- COA date significantly older than shipping date — may indicate the document is being reused
Third-party vs in-house testing
This is the most important distinction in the entire document. Every other aspect of COA quality is secondary to whether the testing was performed by an independent laboratory or by the vendor themselves.
In-house testing means the vendor tested their own product in their own facility and reported the results. There is a direct financial incentive to report favorable numbers. Without independent verification, in-house results are unverifiable claims.
Third-party testing means an independent, separately operating laboratory received a sample and tested it without any financial relationship with the vendor that would create pressure to produce favorable results. The laboratory's name and accreditation can be independently verified.
Recognised testing laboratories
Common third-party labs used by reputable peptide vendors include Janoshik Analytical, Freedom Diagnostics, Peptide Test (associated with the research community), and BioRegen. These are real, independently verifiable organizations. If a COA names a laboratory you cannot find any information about online, treat it as a red flag.
| Testing type | Trustworthiness | What it means |
|---|---|---|
| Named third-party lab | Verifiable | Highest confidence — independent verification |
| Community-submitted test | Verifiable | Buyer-initiated third-party testing — very credible |
| In-house testing | Unverifiable | Vendor grading their own work — limited value |
| No COA provided | Reject | No documentation — do not purchase |
| Unverifiable lab name | Reject | Possible fabrication — do not purchase |
The complete pre-purchase checklist
Before placing any peptide order, run through these checks against the vendor's COA:
How PeptideComparison uses COAs in scoring
COA quality is the single most weighted criterion in PeptideComparison's vendor scoring system — it counts double compared to price, reviews, shipping, or availability. This reflects a deliberate editorial position: in an unregulated market, documentation quality is the only objective safety signal available to buyers.
When we score a vendor's COA, we evaluate four sub-criteria: whether testing is performed by a named third party, whether HPLC chromatograms are publicly available on product pages, whether mass spectrometry identity confirmation is included, and whether lot numbers are traceable to specific vials. A vendor can have competitive pricing and fast shipping but still score poorly on COA if their documentation doesn't meet these standards.
See vendor rankings by COA score →Frequently asked questions
Can I request a COA before buying?
Yes — and you should. Any reputable vendor will provide COA documentation for a specific product before you place an order. Vendors who decline to share COAs prior to purchase, or who claim COAs are proprietary, are operating below the minimum standard of transparency. Many top vendors publish COAs directly on product pages without any request required.
What if the vendor's COA and a community test disagree?
Community-submitted tests — where buyers send their vials to independent labs like Janoshik or Peptide Test — are some of the most credible verification available. They test the actual product that arrived, in the actual vial, for the specific batch a buyer received. If community tests consistently show lower purity than vendor COAs for the same vendor, that is a significant signal of concern. Sites like Finnrick.com aggregate community testing data and are a valuable cross-reference.
Does a high purity percentage guarantee the peptide works?
Purity confirms that what is in the vial is predominantly the stated compound and not impurities or contaminants. It does not guarantee biological activity, correct folding, or any specific research outcome. It is a necessary but not sufficient condition for a usable research peptide. Proper reconstitution, storage, and handling also affect peptide integrity after the vial arrives.
What is the difference between HPLC and LC-MS?
LC-MS (Liquid Chromatography — Mass Spectrometry) is a combined technique that performs HPLC separation and mass spectrometry identity confirmation in a single analytical run. It provides both purity and identity data simultaneously. Some vendors use separate HPLC and MS instruments and report them as two separate tests; others use LC-MS as a combined method. Both approaches are valid. What matters is that both purity and identity data are present in the documentation.